Improving Outcomes in State AIDS Drug Assistance Programs

Background:State AIDS Drug Assistance Programs (ADAPs) provide antiretroviral medications to patients with no access to medications. Resource constraints limit the ability of many ADAPs to meet demand for services. Objective:To determine ADAP eligibility criteria that minimize morbidity and mortality and contain costs. Methods:We used Discrete Event Simulation to model the progression of HIV-infected patients and track the utilization of an ADAP. Outcomes included 5-year mortality and incidence of first opportunistic infection or death and time to starting antiretroviral therapy (ART). We compared expected outcomes for 2 policies: (1) first-come first-served (FCFS) eligibility for all with CD4 count ≤350/μL (current standard) and (2) CD4 count prioritized eligibility for those with CD4 counts below a defined threshold. Results:In the base case, prioritizing patients with CD4 counts ≤250/μL led to lower 5-year mortality than FCFS eligibility (2.77 vs. 3.27 deaths per 1000 person-months) and to a lower incidence of first opportunistic infection or death (5.55 vs. 6.98 events per 1000 person-months). CD4-based eligibility reduced the time to starting ART for patients with CD4 counts ≤200/μL. In sensitivity analyses, CD4-based eligibility consistently led to lower morbidity and mortality than FCFS eligibility. Conclusion:When resources are limited, programs that provide ART can improve outcomes by prioritizing patients with low CD4 counts.

[1]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[2]  J. Fleishman,et al.  Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. , 2000, Journal of acquired immune deficiency syndromes.

[3]  Richard D Moore,et al.  CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  George S. Fishman,et al.  Discrete-Event Simulation : Modeling, Programming, and Analysis , 2001 .

[5]  M. Johnson,et al.  Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures , 2005, AIDS.

[6]  M. Johnson,et al.  96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures , 2006, AIDS.

[7]  Oguzhan Alagoz,et al.  A Clinically Based Discrete-Event Simulation of End-Stage Liver Disease and the Organ Allocation Process , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  T. Buchler,et al.  Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult. , 2008, AIDS.

[9]  K. Whetten,et al.  Association of Race and Gender with Use of Antiretroviral Therapy Among HIV-infected Individuals in the Southeastern United States , 2007, Southern medical journal.

[10]  R. Walensky,et al.  HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  K. Freedberg,et al.  Understanding delay to medical care for HIV infection: the long-term non-presenter , 2001, AIDS.

[12]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[13]  Richard D Moore,et al.  Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001 , 2005, Journal of acquired immune deficiency syndromes.

[14]  J. Sterne,et al.  Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies , 2007, AIDS.

[15]  A. Gładysz,et al.  Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial , 2005, Current medical research and opinion.

[16]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[17]  M. Lederman,et al.  Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol , 2000, The Journal of infectious diseases.

[18]  C. Kemper,et al.  Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. , 1996, The New England journal of medicine.

[19]  J. Levi,et al.  Maximizing Access to Medications through Efficient Use of CARE Act Resources , 2003 .

[20]  B. Gazzard,et al.  Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis , 2006, Journal of acquired immune deficiency syndromes.

[21]  Atlanta,et al.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  J. Fleishman,et al.  Prevalence and Predictors of Highly Active Antiretroviral Therapy Use in Patients With HIV Infection in the United States , 2000 .

[23]  J. Ioannidis,et al.  A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. , 1996, Archives of internal medicine.

[24]  R. Walensky,et al.  Optimizing resource allocation in United States AIDS drug assistance programs. , 2006, Clinical Infectious Diseases.

[25]  J. Montaner,et al.  Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials , 2005, Journal of acquired immune deficiency syndromes.

[26]  C. Katlama,et al.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial , 2007, The Lancet.

[27]  David Dunn,et al.  Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study , 2008, AIDS.

[28]  E. Arias,et al.  United States life tables, 2005. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[29]  M C Weinstein,et al.  The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.

[30]  W. El-Sadr,et al.  Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. , 1998, The New England journal of medicine.

[31]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[32]  M. Kitahata.  Initiating Rather than Deferring Haart at a CD4+ Count Between 351-500 Cells/mm 3 is Associated with Improved Survival , 2008 .

[33]  William C. Grant,et al.  Trends in health care resource use for hepatitis C virus infection in the United States , 2005, Hepatology.

[34]  A. Telenti,et al.  CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. , 2003, Archives of internal medicine.

[35]  Stewart Robinson,et al.  Simulation: The Practice of Model Development and Use , 2004 .